期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
疏肝益精健脾为主中药治疗屈光不正性弱视的临床研究 被引量:10
1
作者 周至安 邱波 骆梅娟 《广州中医药大学学报》 CAS 2008年第2期109-111,共3页
【目的】观察疏肝益精健脾为主的中药对屈光不正性弱视患儿视功能的影响。【方法】将57例符合屈光不正性弱视诊断的患儿随机分为2组,治疗组29例52眼,对照组28例46眼。治疗组采用具有疏肝健脾、益精明目作用的西明汤(主要由郁金、太子参... 【目的】观察疏肝益精健脾为主的中药对屈光不正性弱视患儿视功能的影响。【方法】将57例符合屈光不正性弱视诊断的患儿随机分为2组,治疗组29例52眼,对照组28例46眼。治疗组采用具有疏肝健脾、益精明目作用的西明汤(主要由郁金、太子参、西洋参、枳实、藿香、密蒙花、蕤仁肉、谷芽、麦芽、山楂、神曲等组成)治疗,对照组采用左旋多巴治疗,两组病例还同时进行验光配镜及传统的电脑闪烁增视仪治疗。两组均以7 d为1个疗程,共8个疗程。比较两组治疗前后患儿矫正视力的变化。【结果】治疗组52眼,基本痊愈33眼,进步13眼,无效6眼,总有效率为88.46%;对照组46眼,基本痊愈12眼,进步10眼,无效24眼,总有效率为47.83%。两组疗效比较,治疗组优于对照组(P<0.05)。【结论】疏肝健脾、益精明目为主的中药能有效改善屈光不正性弱视患儿的视功能。 展开更多
关键词 弱视/中药疗法 西明汤/治疗应用 疏肝 健脾 明目
下载PDF
Efficacy and safety of Shaoyang Xibi decoction in patients with knee osteoarthritis:a multi-center,single-blind,randomized controlled trial 被引量:11
2
作者 Si Yuhao Ma Yong +5 位作者 Guo Yang Pan Yalan Zheng Suyang Xu Guihua Da Weiwei Xu Lili 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 2018年第5期733-739,共7页
PURPOSE: To observe the efficacy and safety of Shaoyang Xibi decoction(SYXBD) in patients with knee osteoarthritis(KOA), and to verify that the theory of "Shaoyang dominating bone" in Traditional Chinese Med... PURPOSE: To observe the efficacy and safety of Shaoyang Xibi decoction(SYXBD) in patients with knee osteoarthritis(KOA), and to verify that the theory of "Shaoyang dominating bone" in Traditional Chinese Medicine(TCM) can be applied to KOA treatment.METHODS: Participants were randomly allocated to two groups: SYXBD(treatment group, n = 66)and Meloxicam(control group, n = 66). Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) and 36-Item Short Form Health Survey(SF-36) were used to assess efficacy before the treatment and 8 weeks after the treatment.RESULTS: Baseline data before the treatment between the two groups were similar. The WOMAC scores significantly decreased and the SF-36 scores significantly increased after 8-week treatment in both groups compared with before the treatment(P < 0.05). SYXBD significantly decreased pain scores(P < 0.001), physical function scores(P <0.001) and the total scores(P < 0.001) in WOMAC compared to Meloxicam. SYXBD significantly improved physical function(P = 0.021), bodily pain(P = 0.002) and general health(P = 0.014), with no significant difference in role emotional(P = 0.053),role physical(P = 0.517), vitality(P = 0.241), social function(P = 0.712) and mental health(P = 0.800)in SF-36 compared to Meloxicam. No adverse events were reported in the treatment group while13 adverse events happened in the control group during the study.CONCLUSION: SYXBD, prepared based on the theory of "Shaoyang dominating bone", has a better curative efficay and safety in patients with KOA compared with Meloxicam. The TCM theory of "Shaoyang dominating bone" may be useful in KOA treatment. 展开更多
关键词 Osteoarthritis knee therapeutic useS Shaoyang dominating BONE Kidney dominating BONE Shaoyang Xibi decoction
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部